172 related articles for article (PubMed ID: 28637240)
21. Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift.
Medvetz D; Priolo C; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):3-8. PubMed ID: 25298408
[TBL] [Abstract][Full Text] [Related]
22. Brain lesions in tuberous sclerosis complex. Review.
Grajkowska W; Kotulska K; Jurkiewicz E; Matyja E
Folia Neuropathol; 2010; 48(3):139-49. PubMed ID: 20924998
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
24. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
25. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.
Hoogeveen-Westerveld M; Ekong R; Povey S; Mayer K; Lannoy N; Elmslie F; Bebin M; Dies K; Thompson C; Sparagana SP; Davies P; van Eeghen AM; Thiele EA; van den Ouweland A; Halley D; Nellist M
Hum Mutat; 2013 Jan; 34(1):167-75. PubMed ID: 22903760
[TBL] [Abstract][Full Text] [Related]
26. A novel curcumin analog binds to and activates TFEB in vitro and in vivo independent of MTOR inhibition.
Song JX; Sun YR; Peluso I; Zeng Y; Yu X; Lu JH; Xu Z; Wang MZ; Liu LF; Huang YY; Chen LL; Durairajan SS; Zhang HJ; Zhou B; Zhang HQ; Lu A; Ballabio A; Medina DL; Guo Z; Li M
Autophagy; 2016 Aug; 12(8):1372-89. PubMed ID: 27172265
[TBL] [Abstract][Full Text] [Related]
27. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
[TBL] [Abstract][Full Text] [Related]
28. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
29. Giant Cellular Vacuoles Induced by Rare Earth Oxide Nanoparticles are Abnormally Enlarged Endo/Lysosomes and Promote mTOR-Dependent TFEB Nucleus Translocation.
Lin J; Shi SS; Zhang JQ; Zhang YJ; Zhang L; Liu Y; Jin PP; Wei PF; Shi RH; Zhou W; Wen LP
Small; 2016 Nov; 12(41):5759-5768. PubMed ID: 27593892
[TBL] [Abstract][Full Text] [Related]
30. Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.
Tyburczy ME; Kotulska K; Pokarowski P; Mieczkowski J; Kucharska J; Grajkowska W; Roszkowski M; Jozwiak S; Kaminska B
Am J Pathol; 2010 Apr; 176(4):1878-90. PubMed ID: 20133820
[TBL] [Abstract][Full Text] [Related]
31. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
32. mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model.
Polchi A; Magini A; Meo DD; Tancini B; Emiliani C
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772672
[TBL] [Abstract][Full Text] [Related]
33. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.
Carson RP; Van Nielen DL; Winzenburger PA; Ess KC
Neurobiol Dis; 2012 Jan; 45(1):369-80. PubMed ID: 21907282
[TBL] [Abstract][Full Text] [Related]
34. Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase.
Malik AR; Liszewska E; Skalecka A; Urbanska M; Iyer AM; Swiech LJ; Perycz M; Parobczak K; Pietruszka P; Zarebska MM; Macias M; Kotulska K; Borkowska J; Grajkowska W; Tyburczy ME; Jozwiak S; Kwiatkowski DJ; Aronica E; Jaworski J
Acta Neuropathol Commun; 2015 Jul; 3():48. PubMed ID: 26220190
[TBL] [Abstract][Full Text] [Related]
35. Tuberous sclerosis complex.
Hasbani DM; Crino PB
Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
[TBL] [Abstract][Full Text] [Related]
36. Abnormal Neural Progenitor Cells Differentiated from Induced Pluripotent Stem Cells Partially Mimicked Development of TSC2 Neurological Abnormalities.
Li Y; Cao J; Chen M; Li J; Sun Y; Zhang Y; Zhu Y; Wang L; Zhang C
Stem Cell Reports; 2017 Apr; 8(4):883-893. PubMed ID: 28344003
[TBL] [Abstract][Full Text] [Related]
37. Increased lysosomal biogenesis in activated microglia and exacerbated neuronal damage after traumatic brain injury in progranulin-deficient mice.
Tanaka Y; Matsuwaki T; Yamanouchi K; Nishihara M
Neuroscience; 2013 Oct; 250():8-19. PubMed ID: 23830905
[TBL] [Abstract][Full Text] [Related]
38. A novel mouse model of tuberous sclerosis complex (TSC): eye-specific Tsc1-ablation disrupts visual-pathway development.
Jones I; Hägglund AC; Törnqvist G; Nord C; Ahlgren U; Carlsson L
Dis Model Mech; 2015 Dec; 8(12):1517-29. PubMed ID: 26449264
[TBL] [Abstract][Full Text] [Related]
39. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex.
Tee AR; Sampson JR; Pal DK; Bateman JM
Semin Cell Dev Biol; 2016 Apr; 52():12-20. PubMed ID: 26849906
[TBL] [Abstract][Full Text] [Related]
40. Tsc1 deficiency-mediated mTOR hyperactivation in vascular endothelial cells causes angiogenesis defects and embryonic lethality.
Ma A; Wang L; Gao Y; Chang Z; Peng H; Zeng N; Gui YS; Tian X; Li X; Cai B; Zhang H; Xu KF
Hum Mol Genet; 2014 Feb; 23(3):693-705. PubMed ID: 24129405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
